Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-03-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
澄清公告
Regulatory Filings Classification · 95% confidence The document is a detailed clarification announcement from Kunming Pharmaceutical Group Co., Ltd. regarding changes to its fundraising investment projects. It references prior announcements, approvals by the board and shareholders, and clarifies media reports about changes in the use of raised funds. The document discusses fundraising projects, their changes, and related approvals but does not contain financial statements or quarterly/yearly financial results. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting results announcement. The document is a regulatory announcement clarifying previous fundraising project changes and related corporate actions. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement clarifying fundraising project changes and related corporate governance matters without being a full financial report or other specific filing type.
2017-03-08 Chinese
关于2017年第二次临时股东大会取消议案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation of a proposal for the 2017 second extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the cancellation reasons, meeting dates, voting procedures, and related administrative information. There are no financial statements, audit results, or detailed financial data presented. The document is a formal announcement about shareholder meeting agenda changes and voting arrangements, not a report or transcript. It fits the category of a regulatory announcement related to shareholder meetings but does not contain voting results or detailed meeting materials. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-03-07 Chinese
八届二十七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board resolution by Kunming Pharmaceutical Group Co., Ltd. It details the board meeting held on March 7, 2017, including voting results on a specific agenda item related to canceling a previously proposed change in a fundraising project. The content focuses on board decisions and internal company governance matters rather than financial results, audit information, or shareholder voting outcomes. It is not a full annual or interim report, nor is it a shareholder meeting material or voting result declaration. The document fits the category of Board/Management Information (MANG) as it announces decisions made by the board of directors.
2017-03-07 Chinese
八届十三次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed by the Supervisory Board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the approval of changes to investment projects and amendments to the company's business scope and articles of association. The document includes voting results and mentions that these proposals require further approval by the Board of Directors and shareholders. The content is procedural and governance-related, focusing on board-level decisions and approvals rather than financial results or detailed reports. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement, as it does not report shareholder vote outcomes but rather supervisory board resolutions. Therefore, the document best fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management bodies.
2017-03-03 Chinese
关于增加公司经营范围及修订公司章程的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the increase in the company's business scope and the corresponding amendment to the company's articles of association. It includes details about the original and proposed business scope and mentions the approval process by the board and the need for shareholder meeting approval. The document is short (964 characters) and is a formal announcement of corporate governance changes rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about governance changes. The content fits best under Board/Management Information (MANG) as it relates to changes in company governance and business scope approved by the board and pending shareholder approval.
2017-03-03 Chinese
关于对昆药集团医药商业有限公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase (增资) of a subsidiary company, 昆药集团医药商业有限公司, by the parent company 昆药集团股份有限公司. It details the strategic reasons for the capital increase, the financial status of the subsidiary, the expected impact on the parent company, and risk analysis related to the investment. The document is relatively short (1688 characters) and focuses on a specific financing activity rather than presenting comprehensive financial statements or a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits the category of a Capital/Financing Update, as it announces a capital injection and related strategic investment plans. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-03-03 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.